21989 Investors following Glenmark. Share this News with them.
0
Like this story, share it with millions of investors on M3
Glenmark set to ink multi-billion dollar research deals
Drug maker Glenmark is on the verge of signing a few multi-million dollar research deals, reports CNBC-TV18. The company has been in talks with several European players to out-license its anti-asthma drug.
Drug maker Glenmark is on the verge of signing a few multi-million dollar research deals, reports CNBC-TV18. The company has been in talks with several European players to out-license its anti-asthma drug.
Glenn Saldanha, MD and CEO, Glenmark, said his company's research pipeline looks very robust. "The two that are open right now are 386 for Europe licencing and VR1 antagonist. In addition, our CV1 antagonist 10801 goes into clinical trials from next month. By the end of May we anticipate to start clinicals again in Europe on our CV1 antagonist. We are extremely excited about it. Molecules in Q2 that are going into clinical trials in Europe are GRC4039 which is PD4 and we have one more CB2 agonist for pain, which is GRC10693 that goes into clinicals," he said.
Glenmark has already signed deals for its molecules with US-based Forest Labs and German drug maker Merck.
|
Budget: 2008, 2009, 2010, 2011, 2012 |
Intuit Money Manager |
RBI Credit Policy | Union Budget | Budget 2012
| Economic Survey
| Railway Budget
| Financial Glossary
|
Message Board |
Moneybhai |
Connect.in.com |
Business Yellow Pages |
India's Premiere Technology Guide | History India
| Up Polls | Latest News
| Uninor | Tata Steel | Standard and Poor's | Aurobindo Pharma | Namma Metro | Mahindra Satyam | Chennai | Reliance Industries | DLF Limited | Vodafone Essar 
Glenmark, said his company's research pipeline looks very robust. "The two that are open right now are 386 for Europe licencing and VR1 antagonist. In addition, our CV1 antagonist 10801 goes into clinical trials from next month. By the end of May we anticipate to start clinicals again in Europe on our CV1 antagonist. We are extremely excited about it. Molecules in Q2 that are going into clinical trials in Europe are GRC4039 which is PD4 and we have one more CB2 agonist for pain, which is GRC10693 that goes into clinicals," he said.
